Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023;113(8):875-884.
doi: 10.1159/000530765. Epub 2023 Apr 20.

Variation in the Dopamine-4-Receptor Gene in Patients with Type 1 Diabetes

Bartosz Słomiński  1 , Maria Skrzypkowska  1 , Małgorzata Myśliwiec  2 , Piotr Trzonkowski  1
Affiliations

Variation in the Dopamine-4-Receptor Gene in Patients with Type 1 Diabetes

Bartosz Słomiński et al. Neuroendocrinology. 2023.

Abstract

Introduction: Because dopaminergic signaling pathways are one of the regulators of autoimmunity, we hypothesize that the -521C>T DRD4 gene polymorphism may associate with the risk of diabetes mellitus type 1 (DM1) and its comorbidities.

Methods: In this case-control study, we have examined 300 patients with DM1 in comparison to 300 healthy age-matched controls. Utilizing the amplification refractory mutation system-polymerase chain reaction method, we have analyzed the -521C>T polymorphism of dopamine D4 receptor-encoding gene. Obtained results have been evaluated according to diabetes comorbidities, inflammatory markers, CD14++CD16-, and CD14+CD16+ monocyte subsets as well as lipid profile.

Results: The key results of our study are as follows: (1) CC genotype and C allele are associated with a reduced risk of DM1 development (OR = 0.593, p = 0.005 and OR = 0.725, p = 0.003, respectively), whereas TT genotype and T allele are associated with a higher risk of DM1 (OR = 1.408, p = 0.04 and OR = 1.380, p = 0.003, respectively); (2) CC genotype is associated with an increased risk of dyslipidemia and retinopathy in diabetic patients (OR = 2.376, p = 0.001 and OR = 2.111, p = 0.01, respectively); (3) CC genotype and C allele carriers had the highest frequency of pro-inflammatory CD16+ monocytes (p = 2*10-4 and 0.04, respectively); (4) the DRD4 -521C>T polymorphism modifies the inflammatory status as well as lipid profile in DM1 patients.

Conclusion: Our data imply that the dopaminergic signaling pathways may play an important role in the etiology of DM1 as well as its comorbidities and will provide a new insight into the DM1 risk management. The -521C>T DRD4 gene polymorphism could be considered a genetic marker to predict susceptibility to DM1 as well as retinopathy and dyslipidemia progress in patients with already established disease.

Keywords: Diabetes mellitus type 1; Dyslipidemia; Monocyte subsets; Retinopathy; rs1800955; −521C>T DRD4 gene polymorphism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Similar articles

See all similar articles

References

    1. Beaulieu J-M, Gainetdinov RR, Sibley DR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011 Mar;63(1):182–217. 10.1124/pr.110.002642. - DOI - PubMed
    1. Tavares G, Martins FO, Melo BF, Matafome P, Conde SV. Peripheral dopamine directly acts on insulin-sensitive tissues to regulate insulin signaling and metabolic function. Front Pharmacol. 2021 Sep;12:713418. 10.3389/fphar.2021.713418. - DOI - PMC - PubMed
    1. Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S. The immunoregulatory role of dopamine: an update. Brain Behav Immun. 2010 May;24(4):525–8. 10.1016/j.bbi.2009.10.015. - DOI - PMC - PubMed
    1. Prado C, Bernales S, Pacheco R. Modulation of T-cell mediated immunity by dopamine receptor D5. Endocr Metab Immune Disord Drug Targets. 2013 Jun;13(2):184–94. 10.2174/1871530311313020007. - DOI - PubMed
    1. Bucolo C, Leggio GM, Drago F, Salomone S. Dopamine outside the brain: the eye, cardiovascular system and endocrine pancreas. Pharmacol Ther. 2019 Nov;203:107392. 10.1016/j.pharmthera.2019.07.003. - DOI - PubMed

Publication types

Grants and funding

This research received no funding.